
Opinion|Videos|November 4, 2024
Community Oncologist Perspective: CD3×CD20 Bispecific Toxicities and Consensus Recommendations
Dr Graff discusses how to operationalize bispecific antibody (BsAb) therapy in community practices by summarizing the toxicities associated with CD3×CD20 BsAbs and presenting consensus recommendations for their management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- This presentation is to do a deep dive into the operationalization of bispecific antibody (BsAb) therapy in community practices.
- Please summarize the toxicities observed with CD3×CD20 BsAbs.
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Community Clinical Trials and the Lung Cancer Pipeline
2
MCED Testing: Preparing for the Next Era of Cancer Risk Assessment
3
Dr Erica Stringer-Reasor on Gedatolisib's FDA Approval in Breast Cancer
4
Navigating CAR T Decision-Making in R/R DLBCL
5





















